Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 14/20 | 0.50 |
| ▸ | LOX | P28300 | 5/20 | 0.40 |
| ▸ | KLKB1 | P03952 | 4/20 | 0.35 |
| ▸ | KLK1 | P06870 | 4/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18049351 | 0.99 | LOXL2 (0.49) | LOXL2LOXKLKB1KLK1KCNH2 | |
| SCHEMBL18069339 | 0.89 | LOXL2 (0.40) | LOXL2LOXKLKB1KLK1KCNH2 | |
| SCHEMBL28506536 | 0.86 | HTR6 (0.40) | LOXL2KCNH2TLR7HTR6 | |
| SCHEMBL18049283 | 0.83 | LOXL2 (0.42) | LOXL2KCNH2TLR7HTR6 | |
| SCHEMBL28514231 | 0.83 | KCNH2 (0.36) | LOXL2KCNH2TLR7HTR6 | |
| SCHEMBL18049191 | 0.83 | LOXL2 (0.52) | LOXL2LOXKLKB1KLK1HTR6 | |
| Hydrochloric Acid SCHEMBL28510677 | 0.83 | KCNH2 (0.36) | LOXL2LOXKCNH2TLR7HTR6 | |
| SCHEMBL18049297 | 0.83 | LOXL2 (0.47) | LOXL2LOXKLKB1KLK1HTR6 | |
| Hydrochloric Acid SCHEMBL18049098 | 0.83 | LOXL2 (0.52) | LOXL2LOXKLKB1KLK1HTR6 | |
| SCHEMBL18049252 | 0.82 | LOXL2 (0.51) | LOXL2LOXKLKB1KLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180057458-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. | 2018-03-01 | — | — | US | claimed |
| EP-3265445-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | Pharmakea, Inc. (US) | 2018-01-10 | — | — | EP | claimed |
| WO-2016144702-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. (US) | 2016-09-15 | — | — | WO | claimed |
| US-11358936-B2 | Lysyl oxidase-like 2 inhibitors and uses thereof | PHARMAKEA, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| US-20210171465-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA INC (US) | 2021-06-10 | — | — | US | disclosed |
| EP-3265445-B1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA INC (US) | 2021-05-05 | — | — | EP | disclosed |
| US-10766860-B2 | Lysyl oxidase-like 2 inhibitors and uses thereof | PHARMAKEA, INC. (US) | 2020-09-08 | — | — | US | disclosed |
| EP-3510404-A1 | CHEMICAL PROBES OF LYSYL OXIDASE-LIKE 2 AND USES THEREOF | Pharmakea, Inc. (US) | 2019-07-17 | — | — | EP | disclosed |
| US-20190192697-A1 | CHEMICAL PROBES OF LYSYL OXIDASK-LIKE 2 AND USES THEREOF | PHARMAKEA, INC. | 2019-06-27 | — | — | US | disclosed |
| WO-2018048928-A1 | CHEMICAL PROBES OF LYSYL OXIDASE-LIKE 2 AND USES THEREOF | PHARMAKEA, INC. (US) | 2018-03-15 | — | — | WO | disclosed |
| US-20180057458-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. | 2018-03-01 | — | — | US | disclosed |
| US-20180057458-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. | 2018-03-01 | — | — | US | disclosed |
| EP-3265445-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | Pharmakea, Inc. (US) | 2018-01-10 | — | — | EP | disclosed |
| WO-2017197088-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY CONDITIONS | PHARMAKEA, INC. (US) | 2017-11-16 | — | — | WO | disclosed |
| WO-2016144702-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. (US) | 2016-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11358936-B2 | Lysyl oxidase-like 2 inhibitors and uses thereof | LOXL2, LOXL1, LOX | LOXL2 1/4885LOX 3/4885KLKB1 2505/4885 |
| US-20210171465-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | LOXL2, LOXL1, LOX | LOXL2 1/4885LOX 3/4885KLKB1 2505/4885 |
| US-10766860-B2 | Lysyl oxidase-like 2 inhibitors and uses thereof | LOXL2, LOXL1, LOX | LOXL2 1/4885LOX 3/4885KLKB1 2505/4885 |
| US-20180057458-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | LOXL2, LOXL1, LOX | LOXL2 1/4885LOX 3/4885KLKB1 2505/4885 |
| US-20190192697-A1 | CHEMICAL PROBES OF LYSYL OXIDASK-LIKE 2 AND USES THEREOF | LOXL2, LOXL1, LOXL3 | LOXL2 1/4885LOX 5/4885KLKB1 3155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.